Current Clinical Trials

Clinical Trials/ResearchCurrent Clinical Trials

We can help you determine the optimal approach. Our clinical trials & other research efforts are summarized below.

Current Clinical Trials for the Brain Tumor Center

ACTIVELY RECRUITING STUDIES

Primary Brain Cancer

  • Aadi: Study to Evaluate ABI-009 (nab-Rapamycin) in Patients with Newly Diagnosed Glioblastoma and Recurrent High Grade Glioma (NCT03463265)
  • Aivita: Phase II Trial to Evaluate AV-GBM-1 in Patients with Newly Diagnosed Glioblastoma (NCT03400917)
  • Boehringer Ingelheim: A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer (NCT02423525)
  • Boston Biomedical: A Study of DSP-7888 Dosing Emulsion in Combination With Bevacizumab in Patients With Recurrent or Progressive Glioblastoma (GBM) Following Initial Therapy (NCT03149003)
  • Diffusion Pharmaceuticals: Study to Evaluate Trans Sodium Crocetinate (TSC) in patients with Newly Diagnosed Glioblastoma (NCT03393000)
  • Medicenna Therapeutics, Inc.: An Open-Label Non-Randomized, Multi-Center Phase-2 Study of Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma (NCT02858895)
  • Nativis: A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM) (NCT02296580)
  • Nativis 109: A Feasibility Study of the Nativis Voyager System in Patients With Recurrent Glioblastoma Multiforme (GBM) (NCT03276268)
  • NovoCure, Ltd.: A Single-Center, Open-Label, Randomized Phase II Study of NovoTTF-200A Alone and Combined With Temozolomide in Patients With Low-Grade Gliomas (NCT02507232)
  • Orbus Therapeutics: A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With Anaplastic Astrocytoma That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy (NCT02796261)
  • PNI/JWCI – PIN: A Longitudinal Assessment of Tumor Evolution in Patients with Brain Cancer – Precision Immunotherapy in the Neoadjuvant (PIN) Setting (NCT03425292)
  • Triphase MRZ-112: Study of Marizomib With Temozolomide and Radiotherapy in Patients With Newly Diagnosed Brain Cancer (NCT02903069)

 

Brain Metastasis

  • Boehringer Ingelheim: A Phase I Dose Escalation and CNS Pharmacokinetic Study of the ErbB Family Inhibitor Afatinib in Patients with Recurrent or Progressive Brain Cancer (NCT02423525)

 

Solid Tumors

  • Incyte Corporation: A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of Pembrolizumab + INCB Combinations in Advanced Solid Tumors (NCT02646748)

 

Quality and Outcomes Research

  • CancerLife2: CancerLife: Patient-Driven Solution in Cancer Care (NCT03371147)
  • CancerLife: Evaluation of a Mobile Digital Solution for Cancer Care and Research: A Feasibility Study (NCT03094741)
  • Family Caregivers: An Exploratory Study of Caregiver Burden Among Family Caregivers of Cancer Patients (NCT03069105)
  • PNI/JWCI – CIPN: An Observational Study of Memantine XR (extended release) and Pregabalin Combination Therapy in Chemotherapy-Induced Peripheral Neuropathy (CIPN)

 

COMPLETED/CLOSED STUDIES

  • AbbVie / RTOG: A Study of ABT-414 in Subjects With Newly Diagnosed Glioblastoma (GBM) With Epidermal Growth Factor Receptor (EGFR) Amplification (NCT02646748)
  • Eli Lilly and Company: A Phase 2 Study of Abemaciclib in Patients With Brain Metastases Secondary to Hormone Receptor Positive Breast Cancer, Non-small Cell Lung Cancer, or Melanoma (NCT02308020)
  • EpiCentRXDose-Escalation Study of RRx-001 in Combination With Whole Brain Radiation in Subjects With Brain Metastases (BRAINSTORM) (NCT02215512)
  • ImmunoCellularA Phase III Randomized Double-Blind, Controlled Study of ICT-107 with Maintenance Temozolomide (TMZ) in Newly Diagnosed Glioblastoma following Resection and Concomitant TMZ Chemoradiotherapy (NCT02546102)
  • Inspyr TherapeuticsEfficacy, Safety and CNS Exposure of G-202 in Patients with PSMA-Positive Recurrent or Progressive Glioblastoma (NCT02876003)
  • Kadmon: Study of Tesevatinib in Subjects With Non-Small Cell Lung Cancer, EGFR Activating Mutation, Prior Treatment With a Tyrosine Kinase Inhibitor, and Brain Metastases or Leptomeningeal Metastases (NCT02616393)
  • Triphase MRZ-108: Phase 2 Trial of Single Agent Marizomib in Progressive or Recurrent Grade IV Malignant Glioma (NCT02330562)

FOR PROVIDERS: Clinical Trials Flyers

For more information, contact the Neuro-oncology Clinical Trials Team at neuro.oncology@jwci.org or 310-829-8265.